We have located links that may give you full text access.
Case Reports
Journal Article
Metastatic and pseudomalignant osteoblastoma: a report of two unusual cases.
Skeletal Radiology 1986
Two unusual cases of osteoblastoma with different responses to radiation therapy are reported. A 15-year-old boy with an aggressive osteoblastoma of the ilium was treated initially with curettage and subsequently with radiation and systemic chemotherapy. The patient died 35 months after his initial presentation with distant metastases which were verified at autopsy. A 12-year-old girl developed a lesion of the femur with clinical and histologic features of aggressive osteoblastoma. Amputation was recommended at the time of recurrence, but the patient declined and radiation therapy was given. The patient was alive and well 14 years after her initial presentation. These cases highlight the biologic diversity of osteoblastoma-like lesions and illustrate the difficulties which may be encountered in attempting to differentiate between benign and malignant forms of this tumor.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app